ReviewCancers2020
Hyaluronic Acid-Based Theranostic Nanomedicines for Targeted Cancer Therapy.
Review in Cancers, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
46 citing papers in PubMed, 138 citations in OpenAlex.
- XN@CuO/HA nanobipyramids trigger FOXO1-GADD45G-mediated cuproptosis and synergy with anti-PD-1 for lung cancer therapy.Materials today. Bio · 2026Article
- Hyaluronic acid capped cubosomes co-loaded with antitumor agents towards the treatment of colorectal cancer.Scientific reports · 2025Article
- Scalable production of hyaluronic acid from Bacillus paralicheniformis PV154040.1 under optimized conditions: a GRAS-based bioprocess for biomedical and cosmetic applications.International microbiology : the official journal of the Spanish Society for Microbiology · 2025Article
- Cancer Immunotherapy Based on the Bidirectional Reprogramming of the Tumor Microenvironment by a "Brakes Off/ Step on the Accelerator" Core-Shell Manganese Phosphate/siPD-L1 Modulator.Exploration (Beijing, China) · 2025Article
- pH/Hyal-responsive vancomycin-loaded chitooligosaccharide nanoparticles for intracellular MRSA infection treatment.Materials today. Bio · 2025Article
- Hyaluronic Acid-Coated SPIONs with Attached Folic Acid as Potential T2 MRI Contrasts for Anticancer Therapies.ACS applied materials & interfaces · 2025Article
- Mesoporous silica nanoparticles--based functional platforms for breast cancer therapy: technological advancements.Frontiers in chemistry · 2025Review
- Pharmacological Potentials and Delivery Strategies of Isoliquiritigenin: Challenges and Advances in Enhancing Bioavailability.Drug design, development and therapy · 2025Review
- Recent advances in targeted drug delivery systems for multiple myeloma.Journal of controlled release : official journal of the Controlled Release Society · 2024Review
- Novel CD44-Targeted Albumin Nanoparticles: An Innovative Approach to Improve Breast Cancer Treatment.International journal of molecular sciences · 2024Article
- Fabrication of the Rapid Self-Assembly Hydrogels Loaded with Luteolin: Their Structural Characteristics and Protection Effect on Ulcerative Colitis.Foods (Basel, Switzerland) · 2024Article
- CD44 in Bladder Cancer.Cancers · 2024Review
- Tumor diagnosis using carbon-based quantum dots: Detection based on the hallmarks of cancer.Bioactive materials · 2024Review
- Fluorescent Graphitic Carbon Nitride (g-CPharmaceuticals (Basel, Switzerland) · 2024Article
- Graphene Oxide Nanoparticles and Organoids: A Prospective Advanced Model for Pancreatic Cancer Research.International journal of molecular sciences · 2024Review
- Glycan-based scaffolds and nanoparticles as drug delivery system in cancer therapy.Frontiers in immunology · 2024Review
- A detailed insight of the tumor targeting using nanocarrier drug delivery system.Drug delivery · 2023Review
- Tapping on the Potential of Hyaluronic Acid: from Production to Application.Applied biochemistry and biotechnology · 2023Review
- Review
- The Hyaluronan/CD44 Axis: A Double-Edged Sword in Cancer.International journal of molecular sciences · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
Hyaluronic acid (HA) is a natural mucopolysaccharide and has many useful advantages, including biocompatibility, non-immunogenicity, chemical versatility, non-toxicity, biodegradability, and high hydrophilicity. Numerous tumor cells overexpress several receptors that have a high binding affinity for HA, while these receptors are poorly expressed in normal body cells. HA-based drug delivery carriers can offer improved solubility and stability of anticancer drugs in biological environments and allow for the targeting of cancer treatments. Based on these benefits, HA has been widely investigated as a promising material for developing the advanced clinical cancer therapies in various formulations, including nanoparticles, micelles, liposomes, and hydrogels, combined with other materials. We describe various approaches and findings showing the feasibility of improvement in theragnosis probes through the application of HA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.